NCAPG and colorectal carcinoma: Our results demonstrated that NCAPG silencing reduced β-catenin as well as downstream targets of the Wnt/β-catenin signaling pathway, i.e., c-myc and cyclin D1 in CRC cells, while overexpression of NCAPG had the opposite effect.